Manganese-based breakthrough aims to make medical scans safer and more accessible
Chalfont St Giles, England, 27 April 2026 – A major step forward in medical imaging is underway as GE HealthCare begins advanced clinical trials of a new MRI contrast agent that could improve how doctors detect diseases. The company has started dosing patients in a large international study, marking an important milestone in diagnostic technology.
The new agent, called mangaciclanol, is designed to help doctors see abnormalities inside the body more clearly during MRI scans. These scans often rely on contrast agents to highlight areas such as tumors or damaged tissues, making diagnosis easier and more accurate.
What makes this innovation different is that it uses manganese instead of gadolinium, which is the standard material used today. While gadolinium-based agents are widely used, there have been concerns about traces remaining in the body after repeated scans. Manganese, on the other hand, is a naturally occurring element in the body and is considered more familiar to human biology.
Early trial results suggest that the new agent performs similarly to existing options in terms of image quality. At the same time, its design may reduce the chances of long-term retention in the body. This could make it especially useful for patients who need frequent imaging, including children and those with chronic conditions.
The clinical trial, known as LUMINA, is being conducted across multiple countries and includes both adult and pediatric patients. It has also received Fast Track designation from the U.S. Food and Drug Administration, which helps speed up the development of medical solutions that address important healthcare needs.
Globally, millions of MRI scans are performed every year, and a large number of them require contrast agents for accurate diagnosis. Experts believe that innovations like this could not only improve patient safety but also reduce supply challenges and environmental concerns linked to current materials.
Although the new agent is still under development and not yet approved for general use, it represents a promising shift toward safer and more efficient medical imaging. If successful, it could reshape how doctors diagnose and monitor diseases in the future.